Their data identified SALL1, TMEM119, P2RY12 as markers of microglia-derived GAMs that dominated the TME of primary tumors and TGFBI, CLEC12A and FXYD5 as markers of MDMs that outnumbered microglia in recurrence and were enriched at pimonidazole (PIMO)-positive hypoxic tumor regions (Figure 2). This evidence concerns the gene TMEM119 and neoplasm.